ONCOLOGY: Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide

Oncology, December 13th, 2007 Reporting from: San Antonio Breast Cancer Symposium, 13-16 December, 2007 Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide STEPHEN JONES, US Oncology Research, Houston REFERENCE: ABSTRACT 12 Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival advantage for the taxane. As Stephen Jones of US Oncology Research explained to Derek Thorne, this advantage was also seen in patients over 65.

You can listen to ONCOLOGY: Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide online on Radio and Podcast. Open the player on this page to stream the available audio.

ONCOLOGY: Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide is an episode from Audio Medica News - Medical News Interviews by Audio Medica.

This episode is 00:05:02 long.

This episode was published on Dec 14, 2007.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Audio Medica News - Medical News Interviews when more episodes are available from the podcast feed.